A carregar...
Eligibility and Preventive Potential for New Evidence-Based Cardiovascular Drugs in Secondary Prevention
IMPORTANCE: Recently, 12 randomized clinical trials (RCTs) have demonstrated the efficacy of novel therapies for mainly secondary prevention of atherosclerotic cardiovascular disease. However, given the potential overlapping eligibility of the RCTs, along with the cost of the new therapies, there ar...
Na minha lista:
| Publicado no: | JAMA Cardiol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Medical Association
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6990962/ https://ncbi.nlm.nih.gov/pubmed/31895459 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2019.4759 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|